Abstract Library

#3234 Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project

Introduction: RAISE aimed to find a surrogate endpoint to early predict treatment efficacy in patients with neuroendocrine tumors (NET). Dissociated response is the inhomogeneous response of the different lesions of a patient. Its prognostic value remains unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Dromain C

Authors: Dromain C, Pavel M, Ronot M, Schaefer N, Mandair D,

Keywords: neuroendocrine tumor, dissociated response, progression-free survival, prediction,

#3229 The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project

Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) assesses treatment response via tumor progression in patients with neuroendocrine tumors (NET). RAISE combined deep learning models (DLM) with sum of the longest diameter (SLD) of liver lesions and chromogranin A (CgA) to find a surrogate endpoint for RECIST to early predict progression-free survival (PFS).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Pavel M

Authors: Pavel M, Dromain C, Ronot M, Schaefer N, Mandair D,

Keywords: neuroendocrine tumor, deep learning models, progression-free survival, prediction,

#3104 Molecular profiling of well-differentiated neuroendocrine tumors: Role of ctDNA

Introduction: Tumor molecular profiling has proven relevant for the clinical management of cancer. Circulating tumor DNA (ctDNA) may be a useful surrogate of tumor tissue when this is insufficient for analysis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Frizziero M, Barriuso J, Kapacee Z, Mansoor W,

Keywords: ctDNA, well-differentiated, neuroendocrine,

#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors

Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lee D, Li M, Baumhover N, Liu D, Sagastume E,

Keywords: prrt, VMT-alpha-NET, 203Pb/212Pb theranostics,

#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors

Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Aberle S

Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,

Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,